{{Drugbox
| Verifiedfields = changed
| verifiedrevid = 477237014
| IUPAC_name = N-acetyl-3-(2-naphthyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridyl)-D-alanyl-L-seryl-N-methyl-L-tyrosyl-D-asparagyl-L-leucyl-N6-isopropyl-L-lysyl-L-prolyl-D-alaninamide<ref>{{cite web| title=Abarelix| website=PubChem| date=2017-07-29| url=https://pubchem.ncbi.nlm.nih.gov/compound/Abarelix}}</ref><!--not validated by [[Wikipedia:WikiProject Pharmacology]]-->
| image = Abarelix.svg
<!--Clinical data-->
| tradename = Plenaxis
| Drugs.com = {{drugs.com|monograph|abarelix}}
| pregnancy_US = X
| legal_status = 
| routes_of_administration = [[Intramuscular injection]]
<!--Pharmacokinetic data-->
| bioavailability =  
| protein_bound = 96–99%
| metabolism = 
| elimination_half-life = 
<!--Identifiers-->
| CAS_number_Ref = {{cascite|changed|??}}
| CAS_number = 183552-38-7
| CAS_supplemental = <!--not validated by [[Wikipedia:WikiProject Pharmacology]]-->
| ATC_prefix = L02
| ATC_suffix = BX01
| ATC_supplemental =  
| PubChem = 16131215
| IUPHAR_ligand = 1188
| DrugBank_Ref = {{drugbankcite|correct|drugbank}}
| DrugBank = DB00106
| ChemSpiderID_Ref = {{chemspidercite|correct|chemspider}}
| ChemSpiderID = 10482301
| UNII_Ref = {{fdacite|correct|FDA}}
| UNII = W486SJ5824
| KEGG_Ref = {{keggcite|correct|kegg}}
| KEGG = D02738
| ChEBI_Ref = {{ebicite|correct|EBI}}
| ChEBI = 337298
| ChEMBL_Ref = {{ebicite|correct|EBI}}
| ChEMBL = 1252
<!--Chemical data-->
| C=72 | H=95
| Cl=1 | N=14
| O=14
| molecular_weight = 1416.06 g/mol
| smiles = O=C(N[C@H](C)C(N)=O)[C@@H]6CCCN6C(=O)[C@H](CCCCNC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC(N)=O)NC(=O)[C@H](Cc1ccc(O)cc1)N(C)C(=O)[C@H](CO)NC(=O)[C@@H](Cc2cccnc2)NC(=O)[C@@H](Cc3ccc(Cl)cc3)NC(=O)[C@@H](\nCc4ccc5ccccc5c4)NC(=O)C
| StdInChI_Ref = {{stdinchicite|correct|chemspider}}
| StdInChI = 1S/C72H95ClN14O14/c1-41(2)32-54(64(93)80-53(17-10-11-30-77-42(3)4)72(101)87-31-13-18-60(87)69(98)78-43(5)63(75)92)81-68(97)58(38-62(74)91)84-70(99)61(37-46-22-27-52(90)28-23-46)86(7)71(100)59(40-88)85-67(96)57(36-48-14-12-29-76-39-48)83-66(95)56(34-45-20-25-51(73)26-21-45)82-65(94)55(79-44(6)89)35-47-19-24-49-15-8-9-16-50(49)33-47/h8-9,12,14-16,19-29,33,39,41-43,53-61,77,88,90H,10-11,13,17-18,30-32,34-38,40H2,1-7H3,(H2,74,91)(H2,75,92)(H,78,98)(H,79,89)(H,80,93)(H,81,97)(H,82,94)(H,83,95)(H,84,99)(H,85,96)/t43-,53+,54+,55-,56-,57-,58-,59+,60+,61+/m1/s1
| StdInChIKey_Ref = {{stdinchicite|correct|chemspider}}
| StdInChIKey = AIWRTTMUVOZGPW-HSPKUQOVSA-N
}}

'''Abarelix''' (trade name '''Plenaxis''') is an injectable [[gonadotropin-releasing hormone]] antagonist ([[Gonadotropin-releasing hormone antagonist|GnRH antagonist]]). It is primarily used in [[oncology]] to reduce the amount of [[testosterone]] made in patients with advanced symptomatic [[prostate cancer]] for which no other treatment options are available.<ref name="Drugs.com">Drugs.com: [http://www.drugs.com/mtm/abarelix.html Abarelix]</ref><ref>{{Cite journal 
| last1 = Boccon-Gibod | first1 = L. 
| last2 = Van Der Meulen | first2 = E. 
| last3 = Persson | first3 = B. -E. 
| doi = 10.1177/1756287211414457 
| title = An update on the use of gonadotropin-releasing hormone antagonists in prostate cancer 
| journal = Therapeutic Advances in Urology 
| volume = 3 
| issue = 3 
| pages = 127–140 
| year = 2011 
| pmid = 21904569 
| pmc =3159401 
}}</ref>

It was originally marketed by Praecis Pharmaceuticals as ''Plenaxis'',<ref name="Drugs.com" /> and is now marketed by Speciality European Pharma in Germany<ref>Pharmazeutische Zeitung online: [http://www.pharmazeutische-zeitung.de/index.php?id=4760 Abarelix] {{de icon}}</ref> after receiving a marketing authorisation in 2005. The drug was introduced in the [[United States]] in 2003, but was discontinued in this country in May 2005 due to poor sales and a higher-than-expected incidence of severe [[allergic reaction]]s.<ref name="Minev2011">{{cite book|author=Boris Minev|title=Cancer Management in Man: Chemotherapy, Biological Therapy, Hyperthermia and Supporting Measures|url=https://books.google.com/books?id=mOdKDLAAd0AC&pg=PA182|date=13 January 2011|publisher=Springer Science & Business Media|isbn=978-90-481-9704-0|pages=182–}}</ref>

==References==
{{Reflist|2}}


{{Gonadotropins and GnRH}}
{{Peptidergics}}

[[Category:GnRH antagonists]]
[[Category:Peptides]]